Given that the MC38‐OVAdim s.c. model thus represented a setting in which anti‐RANKL/PD‐1 demonstrated superior tumor control vs. combination of parental anti‐RANKL plus anti‐PD‐1 antibodies, we investigated the mechanisms related to this efficacy. This evidence concerns the gene TNFSF11 and neoplasm.